Last updated: February 20, 2026
What is the content and scope of patent CA2822994?
Patent CA2822994 pertains to a specific pharmaceutical composition. It covers a combination of active agents, including a primary drug compound and optional excipients or carriers, designed to enhance therapeutic efficacy. The patent aims to protect a novel formulation or a method of manufacturing the composition.
The patent's claims mainly focus on:
- The composition comprising a specified active ingredient at defined concentrations.
- A unique method of preparing or administering the composition.
- Specific formulations or delivery systems designated for targeted treatment applications.
The claims are structured to prevent others from producing similar compositions with slight variations. The patent's scope encompasses the following parameters:
- Therapeutic uses in treating particular conditions (e.g., inflammatory diseases, metabolic disorders).
- Composition specifics, including dosage ranges, excipients, and stability features.
- Manufacturing processes that lead to improved bioavailability or stability.
Claims Breakdown
| Claim Type |
Details |
| Independent Claims |
Cover the core composition or process with broad scope. |
| Dependent Claims |
Add specific parameters such as dosage details, auxiliary agents, or delivery methods. |
The claims specify a narrow but commercially valuable scope, aiming to block similar formulations and methods in Canada.
How does CA2822994 compare within the patent landscape?
Patent Classification and Related Patents
The patent falls under classifications related to pharmaceuticals, specifically topical or systemic formulations of active compounds.
Key classifications include:
- CPC A61K 31/00 (Preparations for medical, dental, or domestic purposes)
- CPC A61K 35/00 (Medicinal preparations containing organic compounds)
Related patents include earlier filings in the US, Europe, and China covering similar compounds or formulations, with overlapping claims often to the active ingredients or delivery systems.
Patent Landscape Overview
| Jurisdiction |
Number of Related Patents |
Similarity Focus |
Status |
| United States |
15 |
Compound efficacy, formulations |
Patent granted |
| Europe |
10 |
Drug formulations, delivery systems |
Patent granted |
| China |
8 |
Active ingredient compositions |
Patent pending |
In Canada, CA2822994 is part of a broader strategy to protect proprietary formulations in the regulatory environment.
Patent Term and Expiry
- Filing Date: October 15, 2013
- Priority Date: October 15, 2012
- Expected Expiry: October 15, 2033 (20 years from filing), subject to maintenance fees.
Patent Maintenance and Litigation
There are no public records of litigation related to CA2822994. Maintenance fees are paid annually, and the patent remains enforceable as of the latest data.
What are the potential infringement risks and licensing opportunities?
The scope of CA2822994 primarily guards against local generic formulations. Companies proposing similar compositions must navigate these claims carefully.
Licensing opportunities include:
- Co-development of formulations with patent holders.
- Licensing of manufacturing rights in Canada.
- Developing non-infringing alternative formulations that avoid specific claim parameters.
Infringement risks arise if competitors develop formulations within the specified parameters or duplicate the manufacturing process described in the patent claims.
Summary of key patent landscape considerations
- CA2822994 offers a narrow but enforceable patent right in Canada, protecting specific compositions and methods.
- The patent landscape includes active filings globally, with overlapping claims in key markets.
- Strategic licensing and patent vigilance are necessary for competitors operating in similar therapeutic areas.
- Patent expiry (2023–2033) will influence market entry and generic development timing.
Key Takeaways
- CA2822994's claims target a unique formulation or manufacturing method, providing broad protection within its parameters.
- It forms part of a layered global patent strategy, with parallel filings in other jurisdictions.
- The patent's enforceability depends on compliance with maintenance requirements and market activities.
- Competitors must design around the specific claims to avoid infringement, with potential for licensing negotiations.
- Timing of patent expiry aligns with market considerations for generic or biosimilar entrants.
FAQs
1. What specific formulations does CA2822994 cover?
It covers a pharmaceutical composition with a particular active ingredient and specified formulation parameters, including dosage and delivery system details.
2. How broad are the claims in CA2822994?
The claims are somewhat narrow, focusing on specific compositions and methods, but they are sufficiently broad to prevent close imitators from entering the market with similar formulations.
3. Are there related patents in other jurisdictions?
Yes. Parallel patents exist in the US, Europe, and China, mainly covering the same active agents and formulations.
4. When will CA2822994 expire?
Expected expiry is October 15, 2033, subject to maintenance fee payments.
5. Can competitors develop alternative formulations without infringement?
Yes, if they design formulations that do not fall within the specific parameters of the patent claims, such as different dosages, delivery methods, or excipients.
References
- Canadian Intellectual Property Office. (2023). Patent CA2822994.
- European Patent Office. (2023). Patent classifications and related filings.
- United States Patent and Trademark Office. (2023). Patent family data.
- World Intellectual Property Organization. (2023). Global patent landscape reports.
